This listing of the claims will replace all prior versions, and listings, of claims in the application:

LISTING OF THE CLAIMS

Claims 1-13 (canceled).

14. (original) A compound having the structure of formula (II)

(II) 

wherein:

R^1, R^2, R^3, R^4, R^5, R^6, R^7, and R^8 are independently selected from the group consisting of hydrogen, C_1-C_{24} alkyl, C_2-C_{24} alkenyl, C_2-C_{24} alkynyl, C_5-C_{20} aryl, C_6-C_{24} alkaryl, C_6-C_{24} aralkyl, halo, hydroxyl, sulfhydryl, C_1-C_{24} alkoxy, C_2-C_{24} alkenyloxy, C_2-C_{24} alkynyloxy, C_5-C_{20} aryloxy, acyl, acyloxy, C_2-C_{24} alkoxycarbonyl, C_6-C_{20} aryloxycarbonyl, halocarbonyl, C_2-C_{24} alkylcarbonato, C_6-C_{20} arylcarbonato, carboxy, carboxylato, carbamoyl, mono-(C_1-C_{24} alkyl)-substituted carbamoyl, di-(C_1-C_{24} alkyl)-substituted carbamoyl, mono-substituted arylcarbamoyl, thiocarbamoyl, carbamido, cyano, isocyano, cyanato, isocyanato, isothiocyanato, azido, formyl, thioformyl, amino, mono- and di-(C_1-C_{24} alkyl)-substituted amino, mono- and di-(C_5-C_{20} aryl)-substituted amino, C_2-C_{24} alkylamido, C_5-C_{20} arylamido, imino, alkylimino, arylimino, nitro, nitroso, sulfo, sulfonato, C_1-C_{24} alkylsulfanyl, arylsulfanyl, C_1-C_{24} alkylsulfinyl, C_5-C_{20} arylsulfinyl, C_1-C_{24} alkylsulfonyl, C_5-C_{20} arylsulfonyl, phosphono, phosphonato, phosphinato, phospho, phosphino, and combinations thereof, and further wherein any two adjacent (*ortho*) substituents may be linked to form a cyclic structure selected from five-membered rings, six-membered rings, and fused five-membered and/or six-membered rings, wherein the cyclic structure is aromatic, alicyclic, heteroaromatic, or heteroalicyclic, and has zero to 4 non-hydrogen substituents and zero to 3 heteroatoms, with the proviso that one but not both of R^2 and R^6 can be amino, mono-substituted amino, or di-substituted amino;

R^{11} and R^{12} are independently selected from the group consisting of hydrogen, C_1-C_{24} alkyl, C_2-C_{24} alkoxycarbonyl, amino-substituted C_1-C_{24} alkyl, (C_1-C_{24} alkylamino)-substituted C_1-C_{24} alkyl, and di-(C_1-C_{24} alkyl)amino-substituted C_1-C_{24} alkyl;

R^{13} and R^{14} are defined as for R^1, R^2, R^3, R^4, R^5, R^6, R^7, and R^8, with the proviso that at least one of R^{13} and R^{14} is other than hydrogen; and

X is O, S, arylene, heteroarylene, $CR^{15}R^{16}$ or NR^{17} wherein R^{15} and R^{16} are hydrogen, C_1-C_6 alkyl, or together form $=CR^{18}R^{19}$ where R^{18} and R^{19} are hydrogen or C_1-C_6 alkyl, and R^{17} is as defined for R^{11} and R^{12}.

15. (original) The compound of claim 14, wherein R^1, R^3, R^4, R^5, R^7, and R^8 are hydrogen, and X is $CR^{15}R^{16}$, such that the compound has the structure of formula (IIa)

(IIa)



16. (original) The compound of claim 15, wherein R^2 and R^6 are independently selected from the group consisting of hydrogen, halo, hydroxyl, sulfhydryl, C_1-C_{12} alkyl, C_2-C_{12} alkenyl, C_1-C_{12} alkoxy, C_5-C_{20} aryloxy, C_2-C_{12} alkylcarbonyl, C_6-C_{20} arylcarbonyl, C_2-C_{12} acyloxy, C_2-C_{12} alkoxycarbonyl, C_6-C_{20} aryloxycarbonyl, C_2-C_{12} alkylcarbonato, carboxy, carbamoyl, mono-(C_1-C_{12} alkyl)-substituted carbamoyl, di-(C_1-C_{12} alkyl)-substituted carbamoyl, amino, mono- and di-(C_1-C_{12} alkyl)-substituted amino, C_2-C_{12} alkylamido, C_1-C_{12} alkylsulfanyl, C_1-C_{12} alkylsulfinyl, and C_1-C_{12} alkylsulfonyl.

17. (original) The compound of claim 16, wherein R^2 and R^6 are independently selected from the group consisting of halo, C_1-C_{12} alkyl, C_1-C_{12} alkoxy, C_2-C_{12} alkoxycarbonyl, C_2-C_{12} alkylcarbonato, carbamoyl, mono-(C_1-C_{12} alkyl)-substituted carbamoyl, di-(C_1-C_{12} alkyl)-substituted carbamoyl, C_1-C_{12} alkylsulfanyl, C_1-C_{12} alkylsulfinyl, and C_1-C_{12} alkylsulfonyl.

18. (original) The compound of claim 17, wherein at least one of R^2 and R^6 is C_2-C_{12} alkoxycarbonyl or C_2-C_{12} alkylcarbonato.

19. (original) The compound of claim 15, wherein R^{11} and R^{12} are independently selected from the group consisting of hydrogen, C_1-C_{12} alkyl, C_2-C_{12} alkoxycarbonyl, amino-substituted C_1-C_{12} alkyl, (C_1-C_{12} alkylamino)-substituted C_1-C_{12} alkyl, and di-(C_1-C_{12} alkyl)amino-substituted C_1-C_{12} alkyl.

20. (original) The compound of claim 15, wherein R^{13} and R^{14} are independently selected from the group consisting of hydrogen, C_1-C_{12} alkyl, C_1-C_{12} alkoxy, and C_2-C_{12} alkoxycarbonyl.

21. (original) The compound of claim 15, wherein R^{15} and R^{16} are independently selected from hydrogen and C_1-C_{12} alkyl, or together form $=CR^{18}R^{19}$ where R^{18} and R^{19} are hydrogen or C_1-C_6 alkyl.

22. (original) The compound of claim 15, wherein:

R^2 and R^6 are independently selected from hydrogen and C_2-C_6 alkoxycarbonyl;

R^{11} and R^{12} are independently selected from hydrogen and C_1-C_6 alkyl;

R^{13} and R^{14} are independently selected from hydrogen, C_1-C_6 alkyl, C_1-C_6 alkoxy, and C_2-C_6 alkoxycarbonyl; and

R^{15} and R^{16} are independently selected from hydrogen and C_1-C_6 alkyl, or together form $=CH_2$.

23. (original) The compound of claim 22, wherein:

R^2 and R^6 are independently selected from hydrogen and ethoxycarbonyl;

R^{11} and R^{12} are hydrogen;

R^{13} and R^{14} are independently selected from hydrogen, methyl, and ethoxycarbonyl; and

R^{15} and R^{16} are hydrogen.

24. (original) The compound of claim 23, wherein R^2 and R^6 are ethoxycarbonyl.

Claims 25-53 (canceled)

54. (currently amended) A pharmaceutical composition comprising the compound of any one of claims 14 [[,]] and 15 ~~, 25, 26, 36, and 37~~ in combination with a pharmaceutically acceptable carrier.

55. (original) The composition of claim 54, wherein the pharmaceutically acceptable carrier is suitable for oral administration and the composition comprises an oral dosage form.

56. (original) The composition of claim 55, wherein the oral dosage form is a tablet.

57. (original) The composition of claim 55, wherein the oral dosage form is a capsule.

58. (original) The composition of claim 54, wherein the pharmaceutically acceptable carrier is suitable for parenteral administration and the composition comprises a parenterally administrable formulation.

Claims 59 - 84 (canceled).

85. (currently amended) A method for preventing or treating cancer in a mammalian individual, comprising administering to the individual a therapeutically effective amount of the compound of any one of claims 14 [[,]] and 15~~, 25, 26, 36, and 37~~.

86. (original) The method of claim 85, wherein the cancer is an estrogen-dependent cancer.

87. (original) The method of claim 86, wherein the cancer is of the breast, cervix, uterus, ovaries, or endometrium.

88. (original) The method of claim 87, wherein the cancer is breast cancer.

89. (original) The method of claim 87, wherein the cancer is ovarian cancer.

90. (original) The method of claim 86, wherein the cancer is metastasized.

91. (original) The method of claim 86, wherein the cancer is a drug-resistant cancer.

92. (original) The method of claim 91, wherein the cancer exhibits multiple drug resistance.

93. (original) The method of claim 85, wherein the cancer is a non-estrogen-dependent cancer.

94. (original) The method of claim 93, wherein the cancer is of the prostate, liver, lung, colon or pancreas.

95. (original) The method of claim 93, wherein the cancer is metastasized.

96. (original) The method of claim 93, wherein the cancer is a drug-resistant cancer.

97. (original) The method of claim 96, wherein the cancer exhibits multiple drug resistance.

Claims 98 - 99 (canceled).

100. (currently amended) A method for treating an individual predisposed to or suffering from an estrogen-related condition, disease or disorder other than an estrogen-dependent cancer, comprising administering to the individual a therapeutically effective amount of the compound of any one of claims 14 [[,]] and 15 ~~, 25, 26, 36, and 37~~.

Claims 101 - 102 (canceled).

103. (currently amended) A method for treating an individual predisposed to or suffering from a viral infection, comprising administering to the individual a therapeutically effective amount of the compound of any one of claims 14 [[,]] and 15 ~~, 25, 26, 36, and 37~~.

Claims 104 - 109 (canceled).

110. (original) The method of claim 103, wherein the viral infection is caused by a DNA virus.

111. (original) The method of claim 110, wherein the DNA virus is human papillomavirus.

112. (original) The method of claim 110, wherein the viral infection is a retroviral infection.

Claims 113 - 123 (canceled).